PO.ET06.04 · 实验与分子治疗

垂直抑制自噬通路促进胰腺导管腺癌的生长停滞和凋亡性细胞死亡

Vertical inhibition of the autophagy pathway promotes growth arrest and apoptotic cell death in pancreatic ductal adenocarcinoma

海报缩略图:垂直抑制自噬通路促进胰腺导管腺癌的生长停滞和凋亡性细胞死亡
编号 2986 展板 8 时间 4/20 02:00–05:00 区域 Section 13 主讲 Mallory Roach, BS
分会场 Molecular Targets 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Mallory K. Roach1, Jonathan M. DeLiberty1, Seamus Degan2, Lily M. Pita2, Elyse G. Schechter2, Noah L. Pieper2, Runying Yang2, Mariaelena Pieronon3, Clint A. Stalnecker2, Emanuel Frank Petricoin3, Kirsten L. Bryant2

1Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC,2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC,3Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA

摘要 Abstract

中文摘要
胰腺导管腺癌(PDAC)的生长依赖于自噬。唯一获FDA批准的自噬抑制剂氯喹/羟氯喹(CQ/HCQ)抑制了多种PDAC临床前模型的生长。然而,单独使用CQ或将其与标准治疗联合使用的临床试验表明,CQ的临床疗效有限。为鉴定可作为CQ治疗增敏剂的靶基因,我们进行了以CQ为锚点的CRISPR-Cas9介导的功能缺失筛选。我们鉴定出多个自噬相关基因。这一结果使我们假设,同时抑制自噬通路的两个节点(即垂直抑制)是抑制细胞生长更有效的方法。具体而言,编码VPS34(一种自噬体成核所必需的蛋白)的基因PIK3C3的缺失,使PDAC细胞对CQ治疗增敏。我们通过基因耗竭和使用化合物SAR405的药理抑制两种方式验证了这一发现。此外,对ULK1/2(自噬起始所必需的丝氨酸/苏氨酸激酶)的药理抑制进一步增强了CQ介导的抗增殖效应。我们近期证明,用apilimod抑制脂质激酶PIKfyve可强效抑制PDAC中的自噬。我们发现ULK1/2和VPS34抑制剂治疗均使细胞对PIKfyve抑制增敏。为阐明联合治疗后细胞增殖下降的驱动机制,我们利用基于反相蛋白质芯片(RPPA)的蛋白通路激活映射,探索了自噬依赖性和非依赖性通路。我们确定垂直自噬抑制导致代谢重编程,包括受体酪氨酸激酶和PI3K-AKT-mTORC1信号传导增强。此外,通过监测单独使用CQ或apilimod或与ULK1/2抑制联合治疗后自噬相关蛋白LC3B的水平,我们证明垂直自噬抑制同时损害自噬体形成和自噬体处理。我们还发现,在存在两种自噬抑制剂的情况下,切割型caspase积累更多。我们使用Annexin V凋亡实验验证了这一发现,并证明生长抑制部分归因于凋亡性细胞死亡的增强。总之,我们的发现表明垂直抑制自噬通路更有效地抑制自噬并增加PDAC中的细胞死亡,为采用垂直抑制策略以增强自噬抑制的治疗疗效提供了依据。
查看英文原文 English abstract
Pancreatic ductal adenocarcinoma (PDAC) is dependent on autophagy for growth. The sole FDA approved inhibitor of autophagy, chloroquine/hydroxychloroquine (CQ/HCQ), inhibited the growth of multiple preclinical models of PDAC. However, clinical trials using CQ alone or in combination with standards of care have shown that CQ has limited clinical efficacy. To identify genes to target as sensitizers to CQ treatment, we performed a CQ-anchored CRISPR-Cas9 mediated loss-of-function screen. We identified multiple autophagy-related genes. This result led us to hypothesize that concurrent inhibition of two nodes (i.e. vertical inhibition) of the autophagy pathway is a more effective method of inhibiting cell growth. Specifically, loss of PIK3C3 , the gene that encodes VPS34, a protein essential for autophagosome nucleation, sensitized PDAC cells to CQ treatment. We validated this finding via both genetic depletion and pharmacological inhibition with the compound SAR405. Additionally, pharmacological inhibition of ULK1/2, the serine/threonine kinases critical for autophagy initiation, further reduced CQ-mediated anti-proliferative effects. We recently demonstrated that inhibition of the lipid kinase PIKfyve with apilimod potently suppressed autophagy in PDAC. We found that both ULK1/2 and VPS34 inhibitor treatment sensitized cells to PIKfyve inhibition.To elucidate the mechanisms driving decreased cellular proliferation following combination treatment, we explored both autophagy-dependent and -independent pathways using reverse phase protein array (RPPA) based protein pathway activation mapping. We determined that vertical autophagy inhibition resulted in metabolic rewiring including enhanced receptor tyrosine kinase and PI3K-AKT-mTORC1 signaling. Furthermore, by monitoring levels of the autophagy-related protein LC3B following CQ or apilimod treatment alone or in combination with ULK1/2 inhibition, we demonstrated that vertical autophagy inhibition impairs both autophagosome formation and autophagosome processing, simultaneously. We also found that cleaved caspases accumulated more in the presence of two autophagy inhibitors. We validated this finding using Annexin V apoptosis assays and demonstrated that growth suppression was due in part to enhanced apoptotic cell death. In summary, our findings demonstrate that vertical inhibition of the autophagy pathway more effectively suppresses autophagy and increases cell death in PDAC and provides rationale for a vertical inhibition strategy to enhance the therapeutic efficacy of autophagy inhibition.
利益披露 Disclosure
M. K. Roach, None.. J. M. DeLiberty, None.. S. Degan, None.. L. M. Pita, None.. E. G. Schechter, None.. N. L. Pieper, None.. R. Yang, None.. M. Pieronon, None.. C. A. Stalnecker, None.. E. F. Petricoin, None.. K. L. Bryant, None.

← 返回 AACR 2026 检索